Savara to Present Phase 3 IMPALA-2 Trial Data on Molgramostim for aPAP at ERS Congress 2024

LANGHORNE, Pa.--Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory disorders, has announced the acceptance of its abstract for a poster presentation at the European Respiratory Society (ERS) Congress 2024. The event is scheduled to occur from September 7-11, 2024, in Vienna, Austria. Savara will also sponsor an Industry Symposium during the congress.

The accepted abstract, titled “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life (HRQoL) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from IMPALA-2,” will be featured in Poster Session PS-29. This session focuses on clinical dilemmas of non-idiopathic interstitial lung diseases and is set to take place on September 8, 2024, from 12:30-14:00 CET.

In addition, Savara will host a symposium titled “Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and Management” on September 8, 2024, from 17:30 – 19:00 CET at the ERS Congress Industry Theater. Esteemed speakers for the symposium include Cormac McCarthy, M.D., Ph.D., FRCPI, Elisabeth Bendstrup, M.D., Ph.D., and Francesco Bonella, M.D., Ph.D.

Autoimmune Pulmonary Alveolar Proteinosis (aPAP) is a rare lung disease characterized by the abnormal accumulation of surfactant within the alveoli, the tiny air sacs in the lungs. Surfactant is a mixture of proteins and lipids essential for keeping the alveoli open, preventing collapse. In healthy lungs, old and inactive surfactant is cleared away by alveolar macrophages, a type of immune cell. These macrophages require stimulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly. However, in aPAP, antibodies neutralize GM-CSF, inhibiting the macrophages' ability to clear the excess surfactant. As a result, surfactant builds up in the alveoli, impeding gas exchange and leading to symptoms like shortness of breath, coughing, and fatigue. In severe cases, patients might experience fever, chest pain, or hemoptysis (coughing up blood) if secondary lung infections occur. Long-term repercussions of aPAP can include lung fibrosis and potentially necessitate a lung transplant.

Savara's primary focus is on developing treatments for rare respiratory diseases. Their leading program involves molgramostim nebulizer solution, an inhaled form of GM-CSF that is currently in Phase 3 clinical trials for the treatment of aPAP. This medication is administered using the investigational eFlow® Nebulizer System from PARI Pharma GmbH. The company's management brings extensive experience in addressing rare respiratory conditions, identifying unmet medical needs, and driving the development and commercialization of novel therapies.

Savara, as a clinical-stage biopharmaceutical company, is dedicated to improving the lives of patients with rare respiratory illnesses through innovative treatments. Their ongoing research and development efforts aim to bring effective solutions to conditions like aPAP, offering hope and improved quality of life to those affected by these challenging diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!